760 related articles for article (PubMed ID: 3084648)
1. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
3. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
5. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
6. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
7. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
9. Ultrastructural and functional effects of lipopolysaccharide and interleukin-2 on human NK cells.
Kang YH; Carl M; Watson LP
Scanning Microsc; 1988 Sep; 2(3):1567-86. PubMed ID: 3059478
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
12. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
14. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells.
Itoh K; Platsoucas CD; Balch CM
Cell Immunol; 1987 Sep; 108(2):495-500. PubMed ID: 3113744
[TBL] [Abstract][Full Text] [Related]
15. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes.
Sawada H; Abo T; Sugawara S; Kumagai K
J Immunol; 1988 May; 140(10):3668-73. PubMed ID: 2896211
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
19. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
20. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH
Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
